Thomson Reuters, Washington, DC, USA.
Int J Clin Pract. 2012 Nov;66(11):1042-51. doi: 10.1111/j.1742-1241.2012.03009.x.
This retrospective administrative claims-based study evaluated comparative persistence and adherence to overactive bladder (OAB) medications in US patients with and without diabetes.
Patients ≥ 18 years who initiated OAB medications between 1 January 2005 and 30 June 2008 were analysed from the Truven Health MarketScan Commercial and Medicare Supplemental databases. A 12-month baseline period prior to OAB medication initiation was used to classify patients into diabetes and non-diabetes cohorts, and measure demographic and clinical characteristics. Patients in each cohort were directly matched 1 : 1 based on index year, age, gender and geographic region. Multiple logistic regression was used to compare cohorts on outcomes of ≥ 80% adherence to OAB medications and refilling a second OAB medication prescription. Cox's proportional hazards model compared time to non-persistence with OAB medications between both cohorts.
In total, 36,560 patients were included in each cohort. Compared with the non-diabetes cohort, the diabetes cohort had 21.5% higher odds of ≥ 80% adherence to OAB medications, 16.6% higher odds of filling a second OAB medication prescription and 10.3% lower hazard of non-persistence with OAB medications during a 12-month evaluation period.
Patients with diabetes were more persistent and adherent to OAB medications and had higher odds of filling a second medication prescription than patients without diabetes. Further research is needed to identify factors responsible for these findings.
本回顾性基于行政索赔的研究评估了美国伴有和不伴有糖尿病的膀胱过度活动症(OAB)患者使用 OAB 药物的持续时间和依从性。
从 Truven Health MarketScan 商业和医疗保险补充数据库中分析了 2005 年 1 月 1 日至 2008 年 6 月 30 日期间开始使用 OAB 药物的年龄≥18 岁的患者。在开始使用 OAB 药物前的 12 个月的基线期将患者分为糖尿病和非糖尿病队列,并测量人口统计学和临床特征。在每个队列中,根据索引年、年龄、性别和地理区域对患者进行一对一直接匹配。采用多因素逻辑回归比较两个队列中 OAB 药物的依从性≥80%和再次开第二张 OAB 药物处方的结果。Cox 比例风险模型比较两个队列中 OAB 药物的非持续性时间。
共有 36560 名患者被纳入每个队列。与非糖尿病队列相比,糖尿病队列的 OAB 药物依从性≥80%的可能性高 21.5%,再次开第二张 OAB 药物处方的可能性高 16.6%,在 12 个月评估期间 OAB 药物不持续性的风险低 10.3%。
与无糖尿病患者相比,糖尿病患者对 OAB 药物的持续时间更长、依从性更高,再次开第二种药物的可能性更高。需要进一步研究以确定这些发现的原因。